Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, New York 14642


The purpose of this study is to find out how effectively cervix cancer is controlled when radiation is combined with low-dose chemotherapy (Taxotere) . The use of low-dose Taxotere, once per week, with radiation is a new treatment for cervical cancer. This study will also see how well this treatment regimen can be tolerated.


Inclusion Criteria: - Histologic confirmation of squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix including FIGO (International Federation of Gynecologists and Obstetricians) stage IB to IVA with or without pelvic adenopathy. - No evidence of para-aortic or distant metastases. Must have evaluable disease. - Zubrod Performance Status 0-2 or Karnofsky Performance Status > 60 - Laboratory values must be as follows: White blood cell count: > 3,000/mm3,Absolute granulocyte count: > 1,500/mm3, Hemoglobin > 8.0 g/dl, Platelets: > 100,000/mm3, Serum creatinine: < 2.5 mg/dl, Serum calcium: < 1.3 x institutional upper normal limit,Hepatic criteria as follows: Total Bilirubin < ULN for the institution, - Signed study-specific informed consent p - Age > 18 years. - Peripheral neuropathy must be < grade 1. Exclusion Criteria: - Prior or simultaneous malignancies (other than skin cancer) unless disease-free - Medical illness preventing the use of taxane-based chemotherapy. - Carcinoma of the cervix with the following histology: melanoma, sarcoma, small carcinoid, glassy cell, clear cell, and adenoid cystic. - Previous or current medical or psychiatric illness that would prevent informed consent - Patients known to be infected with HIV or a history of AIDS are excluded. - Prior surgery for carcinoma of the cervix other than a biopsy. - Patients with para-aortic disease. - Previous pelvic radiation therapy or systemic chemotherapy is not permitted. - Women who are pregnant or breast-feeding are excluded from this study. - Previous history of hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80 must be excluded.



Primary Contact:

Principal Investigator
Yuhchyau Chen, MD, Ph.D
Universtiy of Rochester, Dept of Radiation Oncology

Backup Contact:


Location Contact:

Rochester, New York 14642
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.